Clinical researches of breast cancer in China

doi:10.3877/cma.j.issn.1674-0807.2022.01.001

Abstract

Abstract:

China has a large number of breast cancer patients, and the occurrence and development of the disease has unique clinical characteristics. Therefore, it is important to develop drugs and treatment methods for the Chinese population. In the past year, China has independently developed many novel drugs, including cyclin-dependent kinase (CDK) 4/6 inhibitor dalpiciclib, poly ADP-ribose polymerase (PARP) inhibitor pamiparib, antibody-drug conjugate disitamab vedotin (RC48-ADC), and programmed cell death-ligand 1 (PD-L1) monoclonal antibody TQB2450. Meanwhile, new treatment methods for breast cancer has been explored, such as short-course endocrine therapy for breast cancer with low ER expression, exemption from chemotherapy for triple positive breast cancer (ER positive, PR positive, HER-2 positive), exemption from anthracycline use for triple negative breast cancer, and capecitabine for adjuvant intensive chemotherapy, which provides important guidance for the clinical diagnosis and treatment of breast cancer. This paper discussed the hot issues of clinical research on hormone receptor positive breast cancer, HER-2 positive breast cancer and triple negative breast cancer in China.

Key words: Breast neoplasms, Clinical study, Receptors, estrogen, Receptor, erbB-2, Triple negative breast neoplasms

Zhijun Li, Binghe Xu. Clinical researches of breast cancer in China[J]. Chinese Journal of Breast Disease(Electronic Edition), 2022, 16(01): 1-5.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhrxbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0807.2022.01.001

https://zhrxbzz.cma-cmc.com.cn/EN/Y2022/V16/I01/1

References 20

[1]	Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3)：209-249.
[2]	National Institutes of Health, U．S. National Library of Medicine. A similar map is available for all studies in ClinicalTrials.gov[EB/OL]. [2021-06-20]. URL
[3]	Xu B, Zhang Q, Zhang P, et al. Dalpiciclib versus placebo plus fulvestrant in HR+/HER2- advanced breast cancer that relapsed or progressed on previous endocrine therapy (DAWNA-1): A multicenter, randomized, phase 3 study[EB/OL]. [2021-06-20]. https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.1002.
[4]	Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial[J]. Lancet, 2013, 381(9869)：805-816.
[5]	Bartlett J, Sgroi DC, Treuner K, et al. Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen-To Offer More? (aTTom) trial[J]. Ann Oncol, 2019, 30(11)：1776-1783.
[6]	Yu KD, Cai YW, Shao ZM. De-escalation of five years adjuvant endocrine therapy duration in patients with ER-low positive (immunohistochemical 1% to 10%) early-stage breast cancer: A propensity-matched analysis from the prospectively maintained database[EB/OL]. [2021-06-20]. https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.538.
[7]	Sun T, Shi YX, Cui JW, et al. A phase 2 study of pamiparib in the treatment of patients with locally advanced or metastatic HER-2-negative breast cancer with germline BRCA mutation[EB/OL]. [2021-06-20]. https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.1087.
[8]	Yan M, Ouyang Q, Sun T, et al. Pyrotinib plus capecitabine for HER-2-positive metastatic breast cancer patients with brain metastases (PERMEATE): A multicenter, single-arm phase Ⅱ study[EB/OL]. [2021-06-20]. https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.1037.
[9]	Ding XW, Mo WJ, Xie XH, et al. Pyrotinib as neoadjuvant therapy for HER2+ breast cancer: A multicenter, randomized, controlled, phase Ⅱ trial[EB/OL]. [2021-06-20]. https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.574.
[10]	Yuan ZY, Huang JJ, Hua X, et al. Trastuzumab plus endocrine therapy or chemotherapy as first-line treatment for metastatic breast cancer with hormone receptor-positive and HER-2-positive: The sysucc-002 randomized clinical trial[EB/OL]. [2021-06-20]. https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.1003.
[11]	Zhang J, Meng YC, Wang BY, et al. Cyclin-dependent kinase 4/6 (CDK4/6) inhibitor SHR6390 combined with pyrotinib and letrozole in patients with human epidermal growth factor receptor 2-positive (HER2+), hormone receptor positive (HR+) metastatic breast cancer (MBC): Phase Ib study results[EB/OL]. [2021-06-20]. https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.1035.
[12]	Wang JY, Liu YJ, Zhang QY, et al. RC48-ADC, a HER-2-targeting antibody-drug conjugate, in patients with HER2-positive and HER2-low expressing advanced or metastatic breast cancer: A pooled analysis of two studies[EB/OL]. [2021-06-20]. https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.1022.
[13]	Hu XC, Zhang J, Liu RJ, et al. Phase I study of A166 in patients with HER2-expressing locally advanced or metastatic solid tumors[EB/OL]. [2021-11-11]. https://ascopubs.org/doi/10.1200/JCO.2021.39.15_suppl.1024.
[14]	Xue C, Yao HR, Lin Y, et al. Phase I study of LZM005, a HER2 antibody, as monotherapy or in combination with trastuzumab and docetaxel in patients with HER2-positive metastatic breast cancer[EB/OL]. [2021-06-20]. https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.1042.
[15]	Zheng FC, Du F, Wang YS, et al. Efficacy of epirubicin plus cyclophosphamide followed by taxanes versus carboplatin plus taxanes as adjuvant chemotherapy in triple-negative breast cancer: 8.1 years median follow-up on a randomized clinical trial[EB/OL]. [2021-06-20]. https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.529.
[16]	Li J, Yu K, Pang D, et al. Adjuvant capecitabine with docetaxel and cyclophosphamide plus epirubicin for triple-negative breast cancer (CBCSG010): an open-label, randomized, multicenter, phase Ⅲ trial[J]. J Clin Oncol, 2020, 38(16)：1774-1784.
[17]	Yuan ZY, Hua X, Li WZ, et al. Predict the benefit of metronomic capecitabine maintenance in early-stage triple-negative breast cancer: Results from the SYSUCC-001 study[EB/OL]. [2021-06-20]. https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.521.
[18]	Wang JY, Xu BH, Sun T, et al. A phase Ib study of TQB2450 plus anlotinib in patients with advanced triple-negative breast cancer[EB/OL]. [2021-06-20]. https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.1074.
[19]	Chen L, Shao ZM, Wang ZH, et al. Combination of famitinib with camrelizumab plus nab-paclitaxel as first-line treatment for patients with immunomodulatory advanced triple-negative breast cancer (FUTURE-C-PLUS): A prospective, single-arm, phase 2 study[EB/OL]. [2021-06-20]. https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.1007.
[20]	Li DD, Tao ZH, Wang BY, et al. Apatinib plus vinorelbine versus vinorelbine for advanced triple-negative breast cancer with failed first or second-line treatment: The NAN trial[EB/OL]. [2021-06-20]. https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.1075.

Please choose a citation manager

Content to export